Last Updated: 2026-03-24 PT
Progressive supranuclear palsy (PSP) is a 4-repeat (4R) tauopathy characterized by the accumulation of hyperphosphorylated tau in neurons and glia, leading to progressive postural instability, vertical supranuclear gaze palsy, parkinsonism, and cognitive decline. Despite being first described over 60 years ago, fundamental questions about disease mechanisms, biomarkers, and therapeutics remain unresolved[1][2].
PSP represents a critical knowledge gap in neurodegenerative disease research for several reasons: (1) it is the most common atypical parkinsonian syndrome, (2) it shares pathological features with corticobasal syndrome (CBS) and Alzheimer's disease, (3) therapeutic development has been slow with no disease-modifying treatments approved, and (4) the relationship between PSP and other tauopathies remains unclear.
Each knowledge gap is evaluated on four dimensions (0-10 scale, maximum total 40):
| Dimension | What It Measures | High Score Means |
|---|---|---|
| Impact if Solved | Would solving this gap fundamentally change how we treat or prevent PSP? | Could materially alter PSP prevention or treatment |
| Tractability | Is this answerable with current technology? | Can be tested using current cohorts, models, and assays |
| Under-exploration | Are too few researchers working on this? | Important area with insufficient direct effort |
| Data Availability | Do we have datasets, biobanks, models to study this now? | Strong human, fluid-biomarker, and model-system support |
| Rank | Knowledge Gap | Impact | Tractability | Under-exploration | Data | Total | Why It Matters |
|---|---|---|---|---|---|---|---|
| 1 | What determines selective vulnerability of subcortical structures (globus pallidus, substantia nigra, brainstem nuclei) in PSP? | 10 | 6 | 9 | 7 | 32 | Understanding regional vulnerability could reveal protective mechanisms and guide targeted therapies |
| 2 | Can we develop tau PET ligands that specifically detect 4R tau aggregates in vivo? | 10 | 8 | 8 | 6 | 32 | No PSP-specific tau PET exists; this would enable diagnosis and trial enrichment |
| 3 | What is the relationship between PSP and corticobasal syndrome - distinct diseases or spectrum? | 10 | 5 | 8 | 7 | 30 | Overlap at clinical and pathological levels; unclear if shared mechanisms allow shared therapies |
| 4 | Why do some PSP patients show slower progression and longer survival? | 9 | 7 | 8 | 7 | 31 | Identifying resilience factors could reveal protective mechanisms |
| 5 | What drives the clinical heterogeneity across PSP subtypes (Richardson's, PSP-P, PSP-PAGF, etc.)? | 9 | 6 | 8 | 7 | 30 | Subtype-specific mechanisms could enable personalized treatment approaches |
| Rank | Knowledge Gap | Impact | Tractability | Under-exploration | Data | Total | Why It Matters |
|---|---|---|---|---|---|---|---|
| 6 | What is the role of oligodendroglial tau pathology in PSP? | 9 | 7 | 7 | 7 | 30 | Coiled bodies are prominent but understudied in PSP |
| 7 | How does tau spread in PSP - transcellular propagation vs. in situ aggregation? | 9 | 7 | 7 | 7 | 30 | Understanding spread could inform anti-tau therapeutic strategies |
| 8 | What biomarkers predict progression rate and clinical subtype? | 9 | 7 | 7 | 7 | 30 | Biomarkers needed for patient stratification and trial enrichment |
| 9 | What is the relationship between tau haplotypes and PSP risk/phenotype? | 8 | 7 | 7 | 7 | 29 | MAPT haplotypes influence tau biology but role in PSP unclear |
| 10 | Why have anti-tau therapies failed in PSP despite strong biological rationale? | 10 | 5 | 7 | 7 | 29 | Critical for future trial design and mechanism understanding |
| Rank | Knowledge Gap | Impact | Tractability | Under-exploration | Data | Total | Why It Matters |
|---|---|---|---|---|---|---|---|
| 11 | What role does neuroinflammation play in PSP vs. other tauopathies? | 8 | 7 | 7 | 7 | 29 | Microglial activation differs between 4R and 3R/4R tauopathies |
| 12 | Can we identify pre-symptomatic PSP in at-risk individuals? | 8 | 6 | 8 | 6 | 28 | Early detection enables prevention trials |
| 13 | What is the optimal endpoint for PSP clinical trials? | 9 | 6 | 7 | 6 | 28 | Validated endpoints needed for regulatory approval |
| 14 | How does PSP differ from other atypical parkinsonisms at the molecular level? | 8 | 6 | 7 | 7 | 28 | Distinguishing molecular signatures could enable targeted therapies |
| 15 | What is the relationship between PSP and primary age-related tauopathy (PART)? | 8 | 6 | 7 | 6 | 27 | Shared 4R tau but different anatomical distribution |
Core unknown: Why are specific subcortical nuclei (globus pallidus internus, substantia nigra pars reticulata, superior colliculus, brainstem raphe) selectively vulnerable in PSP while cortical involvement remains relatively limited?
What is needed:
Core unknown: Can we develop PET tracers that selectively bind 4R tau aggregates (as in PSP, CBS) vs. 3R/4R tau (as in AD)?
What is needed:
Core unknown: Is PSP a single disease with clinical variants, or are there multiple biologically distinct entities that share some pathological features?
What is needed:
Core unknown: Why do some PSP patients survive 10+ years while others decline rapidly within 3-5 years?
What is needed:
Core unknown: What determines whether a patient develops Richardson's syndrome vs. PSP-parkinsonism vs. PSP-pure akinesia with gait freezing?
What is needed:
| PSP Gap Theme | Shared Disease Context | Related Page |
|---|---|---|
| 4R tauopathy mechanisms | CBS, AGD | 4R Tauopathy Pathway |
| Subcortical vulnerability | PD, MSA | Basal Ganglia Circuit Dysfunction |
| Tau PET development | AD, FTD | Tau PET Ligands |
| Atypical parkinsonism differentiation | PD, MSA, CBS | Parkinsonism Differential Diagnosis |
| Anti-tau therapy failure | AD, FTD | Anti-tau Therapeutics |
| Approach | Status | Evidence Level |
|---|---|---|
| Tau-directed immunotherapy | Trials ongoing | Moderate (PSP-specific data limited) |
| Microtubule stabilizers | Trials failed | Moderate |
| Antisense oligonucleotides (MAPT) | Preclinical | Low |
| Neuroprotective agents | No successful trials | Low |
| Symptomatic treatments (dopamine, amantadine) | Standard of care | Low-moderate |
This section tracks recent publications and advances addressing the knowledge gaps listed above.
HEAD
Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964. ↩︎
Litvan I, et al. National Institute of Neurological Disorders and Stroke Society for Progressive Supranuclear Palsy criteria for progressive supranuclear palsy. Neurology. 2003. ↩︎
Smith R, et al. Tau PET binding in progressive supranuclear palsy and corticobasal syndrome. Neurology. 2025. ↩︎
Boxer AL, et al. Neurofilament light chain as a biomarker in progressive supranuclear palsy. Lancet Neurol. 2024. ↩︎
Chen JA, et al. Genetic modifiers of progressive supranuclear palsy. Brain. 2025. ↩︎
Nicastro N, et al. MRI patterns of subcortical atrophy in progressive supranuclear palsy. Neurology. 2025. ↩︎
Concha-Marambio L, et al. Tau seed amplification in cerebrospinal fluid from progressive supranuclear palsy patients. Acta Neuropathol. 2025. ↩︎
VandeVrede L, et al. Anti-tau antibody trials in 4R tauopathies: lessons learned. Nat Rev Neurol. 2025. ↩︎
Malpetti M, et al. Microglial activation in progressive supranuclear palsy: an TSPO PET study. Brain. 2025. ↩︎